Amgen Inc. (Nasdaq: AMGN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. If approved by the European Commission, Amgen would receive marketing authorization for Prolia in all European Union (EU) Member States…

Here is the original post: 
Amgen Receives CHMP Positive Opinion For Prolia(TM) (Denosumab) In The European Union

You may also like:

• Ambit Biosciences And Astellas Enter Strategic Partnership To Research, Develop And Commercialize FLT3 Kinase Inhibitors In Multiple Indications
• Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis
• Draft NICE Guidance Recommends Tocilizumab For Rheumatoid Arthritis
• GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
• NICE Draft Guidance Gives People Living With Hepatitis C More Treatment Options
• Barrett’s Oesophagus - Ablative Therapy
• Achieving Goals Empowers People With Dementia
• FDA Approves New Labeling For ISENTRESS® To Include 96-Week Efficacy And Tolerability Data In Adult Patients Infected With HIV-1
• Boceprevir Helped Most Chronic Hepatitis C Genotype 1 Infection Patients Achieve Sustained Virologic Response, Primary Endpoint Of Phase III Studies
• GSK Receives CHMP Positive Opinion For A New Indication For Arixtra